AI assistant
ABBOTT LABORATORIES — Director's Dealing 2017
Feb 24, 2017
29777_dirs_2017-02-24_800ca2e5-a4c6-4262-b4a4-3b2d083c5592.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2017-02-16
Reporting Person: STARKS DANIEL J (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common shares without par value | 6401104 | Direct |
| Common shares without par value | 58399 | Direct |
| Common shares without par value | 258 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option (right to buy) | $28.50 | 2018-01-03 | Common shares (168413) | Direct | |
| Option (right to buy) | $33.14 | 2018-01-03 | Common shares (336131) | Direct |
Footnotes
F1: St. Jude Medical, Inc. restricted stock unit award that was converted to an Abbott restricted stock unit award in connection with Abbott's acquisition of St. Jude Medical, in a transaction exempt from Section 16 under Rule 16b-3. The restricted stock units are vested and will settle in shares on July 4, 2017.
F2: Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
F3: St. Jude Medical stock option that was converted to an Abbott stock option in connection with Abbott's acquisition of St. Jude Medical, in a transaction exempt from Section 16 under Rule 16b-3.